BiotechTube

YM178 + tolterodine + Placebo

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Urinary Bladder, Overactive

Conditions

Urinary Bladder, Overactive

Trial Timeline

Apr 5, 2004 → Jan 25, 2005

NCT ID
NCT01604928

About YM178 + tolterodine + Placebo

YM178 + tolterodine + Placebo is a phase 2 stage product being developed by Astellas Pharma for Urinary Bladder, Overactive. The current trial status is completed. This product is registered under clinical trial identifier NCT01604928. Target conditions include Urinary Bladder, Overactive.

What happened to similar drugs?

8 of 20 similar drugs in Urinary Bladder, Overactive were approved

Approved (8) Terminated (0) Active (12)
✅Levofloxacin + LevofloxacinDr. Reddy's LaboratoriesApproved
✅solifenacin succinate + tamsulosin + placeboAstellas PharmaApproved
✅SolifenacinAstellas PharmaApproved
🔄Mirabegron + Tolterodine + Placebo to Mirabegron + Placebo to TolterodineAstellas PharmaPhase 3
✅Levofloxacin + Solifenacin succinate + Placebo (for Solifenacin succinate)Astellas PharmaApproved
🔄solifenacin succinateAstellas PharmaPhase 3
🔄TamuslosinAstellas PharmaPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01604928Phase 2Completed

Competing Products

20 competing products in Urinary Bladder, Overactive

See all competitors
ProductCompanyStageHype Score
Levofloxacin + LevofloxacinDr. Reddy's LaboratoriesApproved
36
Duloxetine + placeboEli LillyPhase 2
35
DuloxetineEli LillyPhase 2
35
Enfortumab vedotinAstellas PharmaPhase 1
21
solifenacin succinate + tamsulosin + placeboAstellas PharmaApproved
43
solifenacin succinate + tamsulosin hydrochloride + Placebo to solifenacin + Placebo to tamsulosinAstellas PharmaPhase 2
35
SolifenacinAstellas PharmaApproved
43
Mirabegron + Tolterodine + Placebo to Mirabegron + Placebo to TolterodineAstellas PharmaPhase 3
40
Levofloxacin + Solifenacin succinate + Placebo (for Solifenacin succinate)Astellas PharmaApproved
39
solifenacin succinateAstellas PharmaPhase 3
40
SolifenacinAstellas PharmaPre-clinical
26
SolifenacinAstellas PharmaPre-clinical
26
TamuslosinAstellas PharmaPhase 3
40
Tamsulosin + SolifenacinAstellas PharmaApproved
43
Alpha blocker + placebo + solifenacinAstellas PharmaApproved
43
mirabegron 25 mg + mirabegron 50 mg + solifenacin 5 mg + solifenacin 10 mg + mirabegron 25 mg matching placebo + mirabegron 50 mg matching placebo + solifenacin 5 mg matching placebo + solifenacin 10 mg matching placeboAstellas PharmaPhase 3
40
solifenacin succinate + tolterodineAstellas PharmaPhase 3
40
TamusulosinAstellas PharmaPhase 3
40
SolifenacinAstellas PharmaPre-clinical
26
Solifenacin succinate + TolterodineAstellas PharmaPhase 3
40